Pharmaceuticals, Biotechnology and Life Sciences
Quantum Pharma, has granted options over 1,100,000 Ordinary Shares of 10 pence each (‘Ordinary Shares’) with an exercise price of 30 pence, to Gerard Murray, Chief Financial Officer.
Nicox, the international ophthalmic R&D company, has provided certain regulatory and clinical updates for NCX 470, its novel nitric oxide…
Asit biotech has completed Phase IIa double-blind placebo-controlled clinical study in house dust mite-induced rhinoconjunctivitis.
Abzena has made application to the London Stock Exchange for the admission of 715,772 new ordinary shares of £0.002 each (‘New Ordinary Shares’) to trading on AIM.
Van Herk Investments B.V. has become owner of more than 10% of Ablynx as it has crossed the 10% threshold and now…
ImmuPharma has appointed Northland Capital Partners as its Nominated Adviser and sole broker with immediate effect. ImmuPharma is a pharmaceutical…
A swedish oncology company Oasmia Pharmaceutical AB, which works on finding cancer cures for animals and humans, said it would move its veterinary assets to the United States.
STADA Arzneimittel AG has named Dr. Barthold Piening as a full Member of the Executive Board with effect from July 1, 2017.
Alliance Pharma’s revenue for 2016, driven by the acquisition of ex-Sinclair products in December 2015, could be more than double compared to the previous year.
Oxford BioDynamics (OBD) has entered into a pilot development agreement with EpiFit PTE. LTD., (EpiFit), a new Singapore based company, to identify epigenetic biomarkers to evaluate predispositions, variations and responses in healthy volunteers undergoing fitness programmes conducted by EpiFit.